"Interleukin-12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
| Descriptor ID |
D018664
|
| MeSH Number(s) |
D12.644.276.374.465.512 D12.776.467.374.465.512 D23.529.374.465.512
|
| Concept/Terms |
Interleukin-12- Interleukin-12
- Natural Killer Cell Stimulatory Factor
- IL-12
- Cytotoxic Lymphocyte Maturation Factor
- IL 12
- Edodekin Alfa
- IL-12 p70
- Interleukin-12 p70
- Interleukin 12 p70
- p70, Interleukin-12
- Interleukin 12
- IL12
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-12".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-12".
This graph shows the total number of publications written about "Interleukin-12" by people in this website by year, and whether "Interleukin-12" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 1 | 2 |
| 1997 | 2 | 0 | 2 |
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 2 | 3 |
| 2001 | 3 | 4 | 7 |
| 2002 | 2 | 1 | 3 |
| 2003 | 5 | 2 | 7 |
| 2004 | 3 | 3 | 6 |
| 2005 | 6 | 4 | 10 |
| 2006 | 1 | 4 | 5 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 3 | 5 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 4 | 6 |
| 2013 | 1 | 3 | 4 |
| 2014 | 3 | 0 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-12" by people in Profiles.
-
IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
-
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat Biomed Eng. 2022 07; 6(7):819-829.
-
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
-
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
-
The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Mar; 84(3):676-690.
-
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng. 2020 05; 4(5):531-543.
-
Secondary resistance to immunotherapy associated with ?-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
-
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
-
The Tale of IL-12 and IL-23: A Paradigm Shift. J Immunol. 2019 02 01; 202(3):629-630.
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.